

## Waiver to Allow Participation in a Food and Drug Administration Advisory Committee

DATE: August 2, 2022

TO: Russell Fortney

Director, Advisory Committee Oversight and Management Staff

Office of the Chief Scientist

FROM: Byron Marshall

Director, Division of Advisory Committee and Consultant Management

Office of Executive Programs

Center for Drug Evaluation and Research

Name of Advisory Committee Meeting Temporary Voting Member: Balazs Halmos, M.D.

**Committee:** Oncologic Drugs Advisory Committee

Meeting date: September 22, 2022


Description of the Particular Matter to Which the Waiver Applies:

Balazs Halmos, M.D., is a temporary voting member of the Oncologic Drugs Advisory Committee (ODAC). The committee's function is to review and evaluate available data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and make appropriate recommendations to the Commissioner of Food and Drugs.

On September 22, 2022, the committee will discuss new drug application (NDA) 215643, for poziotinib tablets, submitted by Spectrum Pharmaceuticals, Inc. The proposed indication (use) for this product is for the treatment of patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 20 insertion mutations. Select patients with NSCLC for treatment with poziotinib based on presence of HER2 exon 20 insertion mutations using an FDA-approved test. The topic of this meeting is a particular matter involving specific parties.

## Type, Nature, and Magnitude of the Financial Interests:

Dr. Halmos is a Professor of Clinical Medicine at Albert Einstein College of Medicine. He is also Section Chief in Thoracic/Head & Neck Medical Oncology and Associate Director of Clinical Research at the Einstein/Montefiore Cancer Center. Dr. Halmos served as the Director of Clinical Cancer Genomics at the Einstein/Montefiore Cancer Center.



Albert Einstein/Montefiore anticipates receiving between \$0 and \$50,000 per year for its participation in the study. Dr. Halmos does not receive any personal remuneration or salary support from this funding.

## Basis for Granting the Waiver:

Dr. Balazs Halmos has unique qualifications and specialized expertise needed for this particular matter.

Dr. Halmos earned his medical degree summa cum laude and completed a residency from Semmelweis University of Medicine in Budapest, Hungary. He also completed an internal medicine residency at St. Luke's-Roosevelt Hospital at Columbia University. Dr. Halmos subsequently completed a hematology/oncology fellowship program as well as a thoracic oncology fellowship program at Beth Israel Deaconess Medical Center. He was a fellow in the clinical investigator training program at Harvard Medical School-Massachusetts Institute of Technology in Boston. Dr. Halmos also earned a Master of Science degree in clinical sciences from Harvard Medical School. Dr. Halmos is board certified in internal medicine, medical oncology, and hematology.

Dr. Halmos' research focuses on molecular testing to guide cancer management, studies of targeted and other agents for the treatment of lung cancer, translational lung cancer biology such as oncogenic tyrosine kinase signaling and treatment resistance. He is an ad hoc reviewer of multiple journals related to oncology and is published in over 100 peer-reviewed articles. Dr. Halmos' extensive experience in medical oncology and lung cancer biology will be helpful in understanding the assessment of benefit and risk in order to provide informative insight.

The particular matter is not sensitive.

This topic is not considered to be sensitive, as the FDA Division responsible for review of poziotinib does not expect that the meeting is likely to receive significant public interest, (non-trade) press interest, nor is it considered highly controversial.

Dr. Balazs Halmos' expertise in this particular matter is necessary in the interest of public health.

Lung cancer is the leading cause of cancer-related mortality in the United States. There are two primary types of lung cancer, known as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Named initially for how the cancer cells look under the microscope, these account for 230,000 newly diagnosed cases of lung cancer in the U.S. each year. The 5-year

relative survival rate from 2010 to 2016 for patients with lung cancer was 21%. The vast majority (85%) of lung cancers fall into the category of NSCLC, of which 70% are classified as non-squamous NSCLC. NSCLC progresses more slowly than SCLC, however 40% of NSCLCs will have distant metastases by the time it is diagnosed.

Early diagnosis offers the best prognosis for NSCLC. However, NSCLC and other lung cancers can be difficult to diagnose because these cancers often have symptoms that are mistaken for common illnesses or from the effects of long-term smoking.

Treatment for NSCLC depends on whether the cancer has spread to other areas of the body, the overall health and age of the patient, and the presence of certain proteins that make treatments more effective. If NSCLC is detected early, surgery to remove the affected tissue or tumor is the treatment of choice. Other treatments include radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The product at issue for the September 22<sup>nd</sup> meeting is Spectrum's poziotinib for the treatment of patients with locally advanced or metastatic NSCLC harboring HER2 exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

In the interest of public health, it is important that the Agency has available the unique expertise that Dr. Halmos will provide for the discussion of the particular matter before the committee.

Any potential for a conflict of interest is greatly outweighed by the strong need for Dr. Balazs Halmos' expertise in this matter.

According to the FDA division responsible for the review of the application, it has been difficult to find individuals with experience in thoracic oncology/lung cancer medicine. Of the five experts identified, one was unable to attend, and one was disqualified due to conflict of interest, leaving only three available to attend, including Dr. Halmos. It is important to have multiple thoracic/lung cancer experts on the panel to discuss the single arm efficacy and safety results observed in Cohort 2 of the ZENITH20 trial in the context of the inadequate dosage optimization for poziotinib with overlapping overall response rates observed at all dose levels evaluated and an improved safety profile with alternative doses/schedules. Dr. Halmos' expertise in lung cancer medicine is needed to provide context to the results presented at the ODAC.

Accordingly, I recommend that you grant Dr. Balazs Halmos, a temporary voting member of the Oncologic Drugs Advisory Committee, a waiver from the conflict-of-interest prohibitions of 18 U.S.C. § 208(a).

## Certification:



The individual may participate, pursuant to 18 U.S.C. 208(b)(3) – The need for the individual's services outweighs the potential for a conflict of interest created by the financial interest involved.

Limitations on the Regular Government Employee's or Special G	overnment Employee's Ability
to Act:	
Non-voting	
Other (specify):	
Denied – The individual may not participate.	
Russell Fortney -S Digitally signed by Russell Fortney -S Date: 2022.08.24 22:12:14 -04'00'	August 24, 2022
Russell Fortney	Date
Director, Advisory Committee Oversight and Management Staff	
Office of the Chief Scientist	